bioAffinity Technologies, Inc. announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and COPD. The partnership integrates bioAffinity's flow cytometry expertise with Pictor's targeted proteomic analysis platform to analyze immune cell populations and cytokine profiles. bioAffinity Technologies, Inc. is a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics.

On July 7, 2026, bioAffinity Technologies, Inc. announced that commercial sales for its noninvasive lung cancer diagnostic, CyPath® Lung, have grown by more than 200% year-over-year. The company operates in the biotechnology industry and develops diagnostic tests for cancer.

bioAffinity Technologies, Inc. consummated a best efforts public offering of 1,040,000 shares of common stock at $0.80 per share and pre-funded warrants to purchase up to 2,960,000 shares of common stock at $0.793 per warrant. The aggregate gross proceeds from the offering were approximately $3.2 million. The company intends to use the proceeds for working capital and general corporate purposes. bioAffinity Technologies, Inc. is a medical technology company that develops and commercializes commercializing diagnostic tools for cancer detection and cancer management.